

-- Table 1:

Sequences of selected anti-ED-B antibody clones

Clone	VH chain			VL chain		
	31-33*	50-54*	95-98*	32*	50*	91-96*
A2	SYA	AISGSG (SEQ ID NO. 27)	GLSI (SEQ ID NO. 29)	Y	G	NGWYPW (SEQ ID NO. 32)
G4	SYA	AISGSG (SEQ ID NO. 27)	SFSF (SEQ ID NO. 30)	Y	G	GGWLPPY (SEQ ID NO. 33)
E1	SYA	AISGSG (SEQ ID NO. 27)	FPFY <u>PFY</u> (SEQ ID NO. 31)	Y	G	TGRIPP (SEQ ID NO. 34)
H10	SFS	SIRGSS (SEQ ID NO. 28)	FPFY <u>PFY</u> (SEQ ID NO. 31)	Y	G	TGRIPP (SEQ ID NO. 34)
L19	SFS	SIRGSS (SEQ ID NO. 28)	FPFY <u>PFY</u> (SEQ ID NO. 31)	Y	Y	TGRIPP (SEQ ID NO. 34)

IN THE CLAIMS:

Please amend claims 19-34 as indicated below (see marked-up copy attached hereto).

19. (Amended) A method for diagnosing a tumor or disease characterized by vascular proliferation, comprising administering to a patient in need of such diagnosis an antibody with specific, high affinity for the ED-B domain of fibronectin.

20. (Amended) A conjugate comprising an antibody with a specific, high affinity for the ED-B domain of fibronectin and a molecule which induces blood coagulation and/or blood vessel occlusion.

21. (Amended) A conjugate according to claim 20 wherein the molecule which induces blood coagulation and/or blood vessel occlusion is a photoactive molecule.

22. (Amended) A conjugate according to claim 21 wherein the photoactive molecule is a photosensitizer.

23. (Amended) A conjugate according to claim 22 wherein the photosensitizer absorbs at a wavelength above 600 nm.

24. (Amended) A conjugate according to claim 22 wherein the photosensitizer is a tin (IV) chlorine e_6 molecule.

25. (Amended) A conjugate according to claim 20 wherein the molecule which induces blood coagulation and/or blood vessel occlusion is a radionuclide.

26. (Amended) A conjugate according to claim 25 wherein the radionuclide is an α - or β - emitting radionuclide.